Robert Radie
Chairman chez ROCKWELL MEDICAL, INC.
Fortune : 223 111 $ au 31/03/2024
Profil
Robert Samuel Radie is currently the Chairman & Chief Executive Officer at Neuraptive Therapeutics, Inc., the Chairman at Rockwell Medical, Inc., and the Director at ValSource LLC.
He previously held positions such as President & Chief Executive Officer at Topaz Pharmaceuticals, Inc., President & Chief Executive Officer at TransMolecular, Inc., Chief Executive Officer at Zyla Life Sciences US LLC, Independent Director at Veloxis Pharmaceuticals A, Director at Egalet Ltd., Director at Affinium Pharmaceuticals Ltd., and Independent Director at Paratek Pharmaceuticals, Inc. He also has experience as a Director at Life Sciences Pennsylvania and Horse Power For Life.
Mr. Radie received his undergraduate degree from Boston College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ROCKWELL MEDICAL, INC.
0,46% | 23/05/2023 | 134 404 ( 0,46% ) | 223 111 $ | 31/03/2024 |
Postes actifs de Robert Radie
| Sociétés | Poste | Début |
|---|---|---|
| ROCKWELL MEDICAL, INC. | Chairman | 01/04/2022 |
Neuraptive Therapeutics, Inc.
 Neuraptive Therapeutics, Inc. BiotechnologyHealth Technology Neuraptive Therapeutics, Inc. engages in developing therapeutic technology for the acute surgical repair of injured peripheral nerves. Its products include AxoFuse, AxoTrim, and AxoBond. The company was founded by David Jackson in 2016 and is headquartered in Lafayette, Co. | Chief Executive Officer | 23/06/2020 |
ValSource LLC
 ValSource LLC Pharmaceuticals: MajorHealth Technology ValSource LLC provides consulting and advisory services to the pharmaceutical, advanced therapy medicinal products, biologics, and medical device industries. The private company is based in Downingtown, PA. The company's services aim to ensure the success and speed-to-market of client projects. | Director/Board Member | 16/11/2020 |
Anciens postes connus de Robert Radie
| Sociétés | Poste | Fin |
|---|---|---|
| PARATEK PHARMACEUTICALS, INC. | Director/Board Member | 21/09/2023 |
Egalet Ltd.
 Egalet Ltd. Pharmaceuticals: MajorHealth Technology Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom. | Chief Executive Officer | - |
| VELOXIS PHARMACEUTICALS A/S | Director/Board Member | 01/02/2020 |
| ZYLA LIFE SCIENCES | Chief Executive Officer | 22/10/2019 |
Zyla Life Sciences US, Inc.
 Zyla Life Sciences US, Inc. Pharmaceuticals: MajorHealth Technology Zyla Life Sciences US, Inc. develops and manufactures pharmaceutical products. The company is headquartered in Wayne, PA. | Chief Executive Officer | 01/10/2019 |
Formation de Robert Radie
| Boston College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| ROCKWELL MEDICAL, INC. | Health Technology |
| PARATEK PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 14 |
|---|---|
Vicuron Pharmaceuticals LLC
 Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
Morphotek, Inc.
 Morphotek, Inc. Miscellaneous Commercial ServicesCommercial Services Morphotek, Inc. operates as a biotechnology company. It develops and distributes biopharmaceutical products. The firm leverages its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. The company was founded by Nicholas C. Nicolaides, Luigi Grasso and Philip M. Sass in May 2000 and is headquartered in Exton, PA. | Commercial Services |
Prestwick Pharmaceuticals, Inc.
 Prestwick Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prestwick Pharmaceuticals, Inc. develops drugs for diseases related to the central nervous system. Its drugs are used in curing diseases such as Huntington's, Parkinson's, restless legs syndrome, schizophrenia, autism, Alzheimer's, and sleep apnea diseases. The company was founded in 2002 and is headquartered in Washington DC. | Health Technology |
Topaz Pharmaceuticals, Inc.
 Topaz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topaz Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on developing and commercializing treatments for the pediatric and dermatology markets. Its lead investigational product is a topical cream formulation of ivermectin which is under development. The firm provides medicines for the treatment of head lice, acne and infections, as well as vaccines against childhood diseases. The company was founded by Donald P. Beeman and Nicholas U. Spring in 2005 and is headquartered in Horsham, PA. | Health Technology |
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
Zyla Life Sciences LLC
 Zyla Life Sciences LLC Pharmaceuticals: MajorHealth Technology Zyla Life Sciences is a commercial-stage company, which focuses on developing, manufacturing and commercializing innovative treatments for pain. It is focused on bringing non-narcotic products and abuse-discouraging formulations of opioids to patients and healthcare providers. The company plans to continue to grow revenue of its seven commercial products, which includes Sprix nasal spray, Vivlodex, Zorvolex, Tivorbex, Indocin suppositories, Indocin oral suspension and oxaydo tablets, and explore business development opportunities. Zyla Life Sciences was founded in August 2013 and is headquartered in Wayne, PA. | Health Technology |
TransMolecular, Inc.
 TransMolecular, Inc. BiotechnologyHealth Technology TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs. | Health Technology |
Egalet Ltd.
Egalet Ltd. Pharmaceuticals: MajorHealth Technology Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom. | Health Technology |
Affinium Pharmaceuticals Ltd.
 Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Health Technology |
Life Sciences Pennsylvania
 Life Sciences Pennsylvania Miscellaneous Commercial ServicesCommercial Services Life Sciences Pennsylvania (LSPA) is a trade association that represents various entities in the life sciences industry, including biotechnology, medical device, diagnostic, pharmaceutical, research, and investment companies, as well as service providers. The non-profit company is based in Wayne, PA and has subsidiaries in the United States. The organization unifies innovators in the state to make Pennsylvania a leader in the life sciences industry. Founded in 1989, LSPA aims to create a business and public policy environment that encourages and incentivizes the diverse life sciences economy in Pennsylvania. Christopher P. Molineaux has been the CEO of the company since 2009. | Commercial Services |
| Horse Power For Life | |
Zyla Life Sciences US, Inc.
Zyla Life Sciences US, Inc. Pharmaceuticals: MajorHealth Technology Zyla Life Sciences US, Inc. develops and manufactures pharmaceutical products. The company is headquartered in Wayne, PA. | Health Technology |
Neuraptive Therapeutics, Inc.
Neuraptive Therapeutics, Inc. BiotechnologyHealth Technology Neuraptive Therapeutics, Inc. engages in developing therapeutic technology for the acute surgical repair of injured peripheral nerves. Its products include AxoFuse, AxoTrim, and AxoBond. The company was founded by David Jackson in 2016 and is headquartered in Lafayette, Co. | Health Technology |
ValSource LLC
ValSource LLC Pharmaceuticals: MajorHealth Technology ValSource LLC provides consulting and advisory services to the pharmaceutical, advanced therapy medicinal products, biologics, and medical device industries. The private company is based in Downingtown, PA. The company's services aim to ensure the success and speed-to-market of client projects. | Health Technology |
